Status:
COMPLETED
Interest of a Systematic One-year Monitoring by 18F-FDG PET-CT
Lead Sponsor:
University Hospital, Brest
Conditions:
Malignant Lymphoma
Relapsed Non Hodgkin Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
In the study, we aimed to characterize the role of FDG PET/CT surveillance at 12 months of malignant lymphoma in asymptomatic patients after a first complete remission and to define a rational follow-...
Detailed Description
Most aggressive lymphomas are sensitive to first-line immunochemotherapy and are in first Complete Remission (CR) with initial therapy. CR significantly decreases the risk of recurrence and increases ...
Eligibility Criteria
Inclusion
- first diagnosis of aggressive lymphoma, complete metabolic remission after a first-line of chemotherapy, no relapse in the first year after the end of treatment
Exclusion
- minor patient, pregnant woman, legal protection (legal curatorship / guardianship), absence of consent
Key Trial Info
Start Date :
January 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2018
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04464590
Start Date
January 1 2009
End Date
December 31 2018
Last Update
July 9 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.